CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - United Arab Emirates is a 266 pages, 2014 market research report now available with ReportsnReports.com. This research says the United Arab Emirates (UAE) is second only to Saudi Arabia in terms of pharmaceutical investment in Middle East countries, with the creation of tax-exempt drug development zones helping to ensure excellent growth prospects. It states that medical tourism, straightforward regulatory guidelines and increasing healthcare expenditure will also be key factors driving the UAE's pharmaceutical market, which is forecast to be worth $3.7 billion by 2020.